Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms

Pharmaceuticals

Volumn 5, Issue 9, 2012, Pages 890-898

  Lu, Xiangyi ^a   Wang, Luan ^a,b   Ruden, Douglas M ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploidy; Cancer; Chaperones; DNA methylation; Epigenetics; Genetic capacitor; Hsp90; Nuclear hormone receptors; Transcriptional pausing

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ELONGATION FACTOR; FLUDARABINE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE H3; LYSINE; MEMBRANE PROTEIN; NEGATIVE ELONGATION FACTOR; SNX 7081; TRITHORAX PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB; XL 888;

ANEUPLOIDY; APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL SURVIVAL; COMPLEX FORMATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; EPIGENETICS; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOSITY; HUMAN; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOLECULAR INTERACTION; NONHUMAN; PHENOTYPIC VARIATION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR PROMOTER GENE; TUMOR SUPPRESSOR GENE;

EID: 84866538272     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5090890     Document Type: Review

References (35)

1. Darwin, C. Variation in Animals and Plants under Domestication; Appleton and Co.: New York, NY, USA, 1883
2. Darwin, C. The Origin of the Species; Suriano, G., Ed.; Random House: London, UK, 1859
3. Lamarck, J.B.P. Zoological Philosophy; Chicago Press: Chicago, IL, USA, 1809
4. Ruden, D.M.; Jamison, D.C.; Zeeberg, B.R.; Garfinkel, M.D.; Weinstein, J.N.; Rasouli, P.; Lu, X. The EDGE hypothesis: Epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancer. Front. Neuroendocrinol. 2008, 29, 428-444
5. Ruden, D.M.; Xiao, L.; Garfinkel, M.D.; Lu, X. Hsp90 and environmental impacts on epigenetic states: A model for the trans-generational effects of diethylstibesterol on uterine development and cancer. Hum. Mol. Genet. 2005, 14, R149-R155
6. Taipale, M.; Jarosz, D.F.; Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528
7. Dezwaan, D.C.; Freeman, B.C. HSP90: The Rosetta stone for cellular protein dynamics? Cell Cycle 2008, 7, 1006-1012
8. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772
9. Rutherford, S.; Hirate, Y.; Swalla, B.J. The Hsp90 capacitor, developmental remodeling, and evolution: The robustness of gene networks and the curious evolvability of metamorphosis. Crit. Rev. Biochem. Mol. Biol. 2007, 42, 355-372
10. Queitsch, C.; Sangster, T.A.; Lindquist, S. Hsp90 as a capacitor of phenotypic variation. Nature 2002, 417, 618-624
11. Ruden, D.M.; Garfinkel, M.D.; Sollars, V.E.; Lu, X. Waddington's widget: Hsp90 and the inheritance of acquired characters. Semin. Cell Dev. Biol. 2003, 14, 301-310
12. Sollars, V.; Lu, X.; Xiao, L.; Wang, X.; Garfinkel, M.D.; Ruden, D.M. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat. Genet. 2003, 33, 70-74
13. Rutherford, S.L.; Lindquist, S. Hsp90 as a capacitor for morphological evolution. Nature 1998, 396, 336-342
14. Meiklejohn, C.D.; Hartl, D.L. A single mode of canalization. Trends Ecol. Evol. 2002, 17, 468-473
15. Lu, X.; Xiao, L.; Wang, L.; Ruden, D.M. Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 2011, 83, 995-1004
16. McLaren, A. Too late for the midwife toad: Stress, variability and Hsp90. Trends Genet. 1999, 15, 169-171
17. Waddington, C.H. Genetic Assimilation of an acquired character. Evolution 1953, 7, 118-126
18. Waddington, C.H. Canalization of development and the inheritance of acquired characters. Nature 1942, 150, 563-565
19. Jablonka, E.; Lamb, M.J. Evolution in Four Dimensions: Genetic, Epigenetic, Behavioral, and Symbolic Variation in the History of Life, Lif and Mind; The MIT Press: Cambridge, MA, USA, 2005; pp. X, 462
20. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410
21. Chen, G.; Bradford, W.D.; Seidel, C.W.; Li, R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature 2012, 482, 246-250
22. Gerson, S.L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4, 296-307
23. Solar, P.; Horváth, V.; Kleban, J.; Koval', J.; Solárová, Z.; Kozubík, A.; Fedorocko, P. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma 2007, 54, 127-130
24. Vasilevskaya, I.A.; Rakitina, T.V.; O'Dwyer, P.J. Geldanamycin and its 17-allylamino-17- demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: Differential caspase activation as a basis for interaction. Cancer Res. 2003, 63, 3241-3246
25. Kwon, H.M.; Kim, Y.; Yang, S.I.; Kim, Y.J.; Lee, S.H.; Yoon, B.W. Geldanamycin protects rat brain through overexpression of HSP70 and reducing brain edema after cerebral focal ischemia. Neurol. Res. 2008, 30, 740-745
26. McLean, P.J.; Klucken, J.; Shin, Y.; Hyman, B.T. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 2004, 321, 665-669
27. McCollum, A.K.; Lukasiewicz, K.B.; Teneyck, C.J.; Lingle, W.L.; Toft, D.O.; Erlichman, C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol. Cancer Ther. 2008, 7, 3256-3264
28. Paraiso, K.H.; Haarberg, H.E.; Wood, E.; Rebecca, V.W.; Chen, Y.A.; Xiang, Y.; Ribas, A.; Lo, R.S.; Weber, J.S.; Sondak, V.K.; et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin. Cancer Res. 2012, 18, 2502-2514
29. Weigert, O.; Lane, A.A.; Bird, L.; Kopp, N.; Chapuy, B.; van Bodegom, D.; Toms, A.V.; Marubayashi, S.; Christie, A.L.; McKeown, M.; et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 2012, 209, 259-273
30. Reddy, M.M.; Deshpande, A.; Sattler, M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin. Ther. Targets 2012, 16, 313-324
31. Best, O.G.; Che, Y.; Singh, N.; Forsyth, C.; Christopherson, R.I.; Mulligan, S.P. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: A potential treatment strategy for fludarabine refractory disease. Leuk. Lymphoma 2012, 53, 1367-1375
32. Tariq, M.; Nussbaumer, U.; Chen, Y.; Beisel, C.; Paro, R. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc. Natl. Acad. Sci. USA 2009, 106, 1157-1162
33. Sawarkar, R.; Sievers, C.; Paro, R. Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 2012, 149, 807-818
34. Nechaev, S.; Adelman, K. Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation. Biochim. Biophys. Acta 2011, 1809, 34-45
35. Pigliucci, M.; Müller, G. Konrad Lorenz Institute for Evolution and Cognition Research, Evolution, the Extended Synthesis 2010, VIII; The MIT Press: Cambridge, MA, USA, 2010; pp. 495.